Table 2.
Factors associated with the new onset of HCC after HBV NAs use.
| New onset HCC | Yes, n = 76 | No, n = 1273 | P value | Cox-regression analysis | ||
|---|---|---|---|---|---|---|
| HR | 95% C.I. | P value | ||||
| Age > 50 years old, n (%) | 53 (69.7) | 517 (40.6) | < 0.001 | 3.64 | 2.03–6.54 | < 0.001 |
| Male, n (%) | 65 (85.5) | 912 (71.6) | 0.008 | 2.69 | 1.29–5.60 | 0.01 |
| Diabetes, n/N (%) | 17/68 (25.0) | 164/1154 (14.2) | 0.02 | 1.20 | 0.64–2.25 | 0.58 |
| BMI (kg/m2, mean [SD])a | 26.1 (4.1) | 24.5 (4.1) | 0.001 | 1.10 | 1.03–1.18 | 0.004 |
| Platelet count (×103u/L, mean (SD)) | 117.1 (70.2) | 169.3 (73.3) | < 0.001 | 0.997 | 0.995–1.000 | 0.07 |
| AST (IU/L, mean (SD)) | 146.2 (183.9) | 309.1 (628.3) | < 0.001 | 1.001 | 1.000–1.003 | 0.14 |
| ALT (IU/L, mean (SD)) | 149.7 (186.0) | 422.6 (649.1) | < 0.001 | 0.997 | 0.995–1.000 | 0.03 |
| Creatinine (mg/dL, mean (SD)) | 1.0 (0.8) | 1.0 (1.1) | 0.81 | |||
| HBV DNA (log10 IU/mL, mean (SD))b | 5.6 (1.7) | 5.9 (1.9) | 0.12 | 0.96 | 0.81–1.14 | 0.61 |
| HBV DNA > 2000 IU/mL, n/N (%) | 65/75 (86.7) | 1134/1271 (89.2) | 0.45 | |||
| HDV RNA positivity, n (%) | 2 (2.6) | 11 (0.9) | 0.16 | 5.73 | 1.35–24.29 | 0.02 |
| HBeAg positivity, n/N (%) | 22/75 (29.3) | 501/1264 (39.6) | 0.09 | 1.21 | 0.60–2.45 | 0.60 |
| Liver cirrhosis, n (%) | 62 (81.6) | 230 (25.9) | < 0.001 | 9.98 | 5.11–19.46 | < 0.001 |
| ETV/TDF/other NAs, n/n/n | 41/5/30 | 569/159/545 | 0.17 | 1.04 | 0.67–1.61 | 0.88 |
| Duration of NAs usage (months, mean (SD)) | 38.4 (24.0) | 26.0 (23.4) | – | |||
| Follow-up period (months, mean (SD)) | 36.7 (35.1) | 48.8 (37.6) | – | |||
| Follow-up period (months, median (range)) | 23.5 (3–130) | 41.0 (3–184) | – | |||
SD: standard deviation; BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HDV: hepatitis D virus; HBeAg: hepatitis B e-antigen; FIB-4: fibrosis-4 index; HCC: hepatocellular carcinoma; NAs: nucleotide analogues; ETV: entecavir; TDF: tenofovir disoproxil fumarate; HR: hazard ratio; CI: confidence interval.
an = 1309.
bn = 1346.